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Puto, M.1, Adel, N.1, Riedel, E.2, Giralt, S.A.3,4, Matasar, M.J.3,4 1Me-
morial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
Sloan-Kettering Cancer Center, New York, NY; 3Memorial Sloan-Ket-
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Background: Despite the use of 5-HT3 antagonists and corticoste-
roids, control of nausea and vomiting (N/V) from high-dose therapy
with autologous stem cell rescue (HDT) remains a clinical challenge.
Routine antiemetic prophylaxis atMemorial Sloan-KetteringCenter
(MSKCC) for pts undergoingHDT is continuous infusion ondanse-
tron and daily dexamethasone. Pts with lymphoma receiving HDT
receive conditioning based upon either RT or chemotherapy;
patients with regional disease may also receive hyperfractionated in-
volved-field RT immediately prior to HDT. The objective of this
study is to evaluate the incidence and predictors of nausea and vom-
iting in pts with lymphoma receiving HDT.
Methods:We performed a retrospective chart review of all sequen-
tial pts with lymphoma receiving HDT between 1/1/2004 and 12/
31/2009 via chart abstraction, review of the pharmacy database and
electronic medical record. Data collected include pt demographics,
diagnosis and therapy, social history, preparative regimen, prophy-
lactic and breakthrough antiemetic use, and instances of N/V. Vom-
iting was defined as recorded instances of vomiting, and nausea as
recorded instances of nausea.
Results: 280 pts were eligible for analysis (Table 1). 54 (19%)
received a TBI/TLI-based therapy, predominantly TLI with cy-
clophosphamide and etoposide, and 226 (81%) received chemo-
therapy-based therapy, predominantly BEAM (173/226, 77%);
immediately prior to conditioning, 83 (30%) received an involved
field RT boost to a site in the neck, chest, or abdomen. The in-
cidence of N/V during the hospital stay for HDT was 85%, and
during conditioning was 74%. 57% of patients had one or more
episodes of vomiting. Women were more likely to experience N/V
than men (94% vs. 80%, P\ 0.001). Patients receiving TBI/TLI-
based therapy had a greater incidence of N/V than did patients
receiving chemotherapy preparative regimens (P\ 0.01) and a lon-
ger duration of N/V (median days, 8 vs. 4). Pretransplant RT boost
was associated with a trend towards a greater incidence of N/V
(92% vs. 83%, P 5 0.09).
Conclusion: In our single-institution experience, pts with lym-
phoma undergoing HDT frequently experience N/V during their
hospitalization despite prophylaxis with ondansetron via continuous
infusion and dexamethasone. Pts receiving RT-based conditioning
or pre-transplant RT appear to be at greater risk yet of N/V. Addi-
tional research into anti-emetic prophylaxis in this patient popula-
tion should be a high priority.
Table 1. Clinical characteristics of patients with lymphoma










N 5 54)Age, median (range) 52 (18-73) 54 (18-73) 33 (20-64)
Gender
Male 171 (61%) 146 (65%) 25 (46%)
Female 109 (39%) 80 (35%) 29 (54%)
Diagnosis
Classical Hodgkin lymphoma 80 (29%) 33 (15%) 47 (87%)
Diffuse large B-cell lymphoma 74 (26%) 72 (32%) 2 (4%)
Mantle cell lymphoma 59 (21%) 56 (25%) 3 (6%)
Follicular lymphoma 21 (8%) 21 (9%) 0
Peripheral T-cell lymphoma 13 (5%) 12 (5%) 1 (2%)
Angioimmunoblastic T-cell lymphoma 9 (3%) 9 (4%) 0
Anaplastic large-cell lymphoma 6 (2%) 6 (3%) 0
Primary CNS lymphoma 9 (3%) 9 (4%) 0
Other 9 (3%) 8 (4%) 1 (2%)315
BUILDING A LEGACY
Bain,M.E., Kurtzberg, J., Cash, J., Martin, P.M. Duke UniversityMed-
ical Center, Durham, NC
Working with children who have life threatening conditions too
often leads to tragic endings. Being a Child Life Specialist (CCLS)
on a pediatric bone marrow transplant unit involves legacy building
and bereavement support for family and loved ones.
Historically, bereavement support at Duke Children’s Hospital
included, among many different things, hand/foot impressions using
plaster. These impressions are best done on infants and toddlers
(small hands). We were in need of a tool that we could use for
school-age and adolescent patients.
Our program helped develop a different kind of hand/foot mold
technique that is made with dental materials. In 2010, a grant was
awarded to the child life specialist working in the pediatric bone
marrow transplant unit to purchase these materials. This new tech-
nique allows for larger hand molds to be made (or multiple hands
at once). Often times, an entire family may want to hold hands and
have a mold made. The material called ‘‘alginate’’ is mixed with wa-
ter to create a paste inside a large disposable cup or basin. The
hand (or hands) is placed in the paste for approximately one minute
or until it hardens and then the hand(s) is removed. Resin rock is
then mixed and poured into the alginate impression. Within one
hour, the resin rock is dry and the alginate can be peeled away.
The child life specialist will then polish and wrap the molds for
presentation to the family.
We have been able to use this technique for .30 children since
2010. The feedback given to our team has been overwhelming. Fam-
ilies have expressed how they can now hold their child’s hand forever.
Some have been eager to emboss themolds in gold. Others have sim-
ply been happy to have something to hold onto as they walk away
from the hospital without their child.
Caring for the suffering and/or dying child is no easy journey. But
with a team of caregivers working together to build a child’s legacy, it
can be done beautifully, honoring the child’s precious life.316
ANXIETY IN BONE MARROW TRANSPLANT PATIENTS
Campos, M., Olaya, A. Instituo Nacional de Pediatria, Mexico, DF,
Mexico
Purpose:Clinical observation has proven that anxiety disorders fre-
quently appears in Bone Marrow transplant (BMT) patientes. It was
decided to conduct a study within the psychological transplant prep-
aration program (PTPP), where the pre-transplant anxiety level was
measured.
Method: A standardized psychological test battery and a semi-
structured interview were conducted on a group of 20 pediatric
patients (5 females/ 15 males, between 6 -18 years old) during
the first session prior to receiving any kind of PTPP. A record
was kept: Age, gender, diagnostic date, hospital stay, clinical com-
plications and family dynamic. Hypothesis testing was conducted
so as to compare percentages, establishing a specificity level f ~N
of 0.5 and a power of 0.8; therefore, estimation according to the
sample size, 20 patients, plus (less) 20% of losses during enroll-
ment was done. Regarding central distribution measurements, hy-
pothesis testing was conducted so as to compared means with
paired ¡V T.
Based on the results, a therapeutic support plan is developed for
handling the patient¡fs anxiety.
Results:Out of the 20 patients assessed, 80% of the patients have
a high anxiety level compared to their chronological age, accord-
ing to what the anxiety scale evaluates. 70% of patients had the
highest number of anxiety indicators within the tests. The statis-
tical analysis showed that variables: a) clinical complications, b)
hospital stay and c) family dynamics were the ones that had
a 90% influence in patients anxiety. Secondly, age, gender and di-
agnostic date were factors that influenced the anxiety status in
64% of the cases.
Conclusion: It is concluded that the anxiety level in BMT patients is
high from the moment they start the process, therefore, it is
